DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Venlafaxine Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
Venlafaxine was the first approved SNRI inhibitor. It was originally developed by Wyeth, a subsidiary of Pfizer, under the trade name Effexor XR. The immediate-release form of venlafaxine for the treatment of depression was marketed in the United States in 1994, and later in 1997, the extended-release form of venlafaxine was approved by the FDA. The extended-release form has a smoother onset of action than the immediate-release form and reaches lower peak concentrations, thus causing fewer adverse effects.
According to the publisher’s market research, in 1998, the generic drug of venlafaxine from Chengdu Kanghong Pharmaceutical Group, Venlafaxine Capsules (trade name: Bolexin) was launched in China, becoming the first domestic venlafaxine product. The original drug, Pfizer’s Effexor XR was not marketed in China until 2001, followed by a number of generic drugs from local Chinese companies. Although Effexor XR was late to enter China’s market, it still holds a major market share. In 2020, Effexor XR accounted for about 50% of the market share in China in terms of sales value.
According to the publisher’s market research, in 2020, because of the impact of COVID-19, Chinese healthcare institutions could not function properly, making the sales value of venlafaxine decrease from that of 2019 to approximately CNY294 million (USD45.2 million), with a CAGR of approximately 7.4% from 2016 to 2020. China’s venlafaxine market is expected to see growth from 2021 to 2025 as COVID-19 is under control in China.
The publisher expects that the rising stress of Chinese residents’ life brought about by the developing economy, rising urbanization, accelerated pace of work and changing interpersonal relationships, the number of depressed patients in China will continue to grow in the future, and the sales volume and value of antidepressants, including venlafaxine, will increase year by year in the Chinese market.
Topics Covered:
- Impact of COVID-19 on China’s Venlafaxine Market
- Development Environment of Venlafaxine in China
- Sales Volume of Venlafaxine in China
- Sales Volume and Value of Venlafaxine in China by Region
- Major Venlafaxine Manufacturers in China and Their Market Shares
- Sales Price of Venlafaxine in China
- Prospects of China’s Venlafaxine Market, 2021-2025
Key Topics Covered:
1 Relevant Concepts of Venlafaxine
1.1 Indications of Venlafaxine
1.2 Development of China’s Venlafaxine Market
1.3 Governmental Approval of Venlafaxine in China
1.4 The Impact of COVID-19 on China’s Venlafaxine Market
2 Sales of Venlafaxine in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Venlafaxine in China by Dosage Form, 2016-2020
2.3.1 Extended-Release Capsules
2.3.2 Extended-Release Tablets
2.3.3 Capsules
2.3.4 Other Dosage Forms
3 Analysis of Major Venlafaxine Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Pfizer Healthcare Ireland
3.2.1 Company Profile
3.2.2 Sales of Venlafaxine in China
3.3 Chengdu Kanghong Pharmaceutical Group
3.3.1 Company Profile
3.3.2 Sales of Venlafaxine in China
3.4 Beijing Winsunny Pharmaceutical Co., Ltd
3.5 Chengdu Beite Pharmaceutical Co., Ltd
3.6 Guizhou Salvage Pharmaceutical Co., Ltd
4 Sales Price of Venlafaxine of Different Companies in China, 2020-2021
4.1 Pfizer Healthcare Ireland (Effexor XR)
4.2 Chengdu Kanghong Pharmaceutical Group (Bolexin)
4.3 Beijing Winsunny Pharmaceutical Co., Ltd (WenYueSi)
4.4 Chengdu Beite Pharmaceutical Co., Ltd (BeiTe)
4.5 Guizhou Salvage Pharmaceutical Co., Ltd (ShengJiLe)
5 Prospects of China’s Venlafaxine Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/9lzxdg
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900